AGORA Cancer Research Center
AGORA was inspired by the vision that the integration of progress in cancer research into clinical practice can be accelerated by bringing together interdisciplinary research teams of clinicians, cancer biologists, immunologists, bio-informaticians and bio-engineers. Initiated by the ISREC Foundation in 2013, the AGORA building was opened in 2018. The functioning of this translational cancer research center reflects a partnership between the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL), the Swiss Federal Institute of Technology of Lausanne (EPFL), the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE).
Latest news
Events
AGORA PRS | September 17th
Events
AGORA Scientific Platform Workshops | September 18th
Events
AGORA Tumor Microenvironment Journal Club | October 4th
Latest publications
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [(99m)Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
Enke JS, Ritzel K, Asbach E, (…), Reincke M, Lapa C, Dierks A
Journal of nuclear medicine – 2024 Sep 5
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.
Ghisoni E, Morotti M, Sarivalasis A, (…), Kandalaft L, Laniti DD, Coukos G
Nature reviews. Clinical oncology – 2024 Sep 4
A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma.
Dimitriou F, Cheng PF, Saltari A, (…), Becher B, Levesque MP, Dummer R
Nature cancer – 2024 Aug 29
Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.
Martin S, Wendlinger L, Zitti B, (…), Faizova R, Viertl D, Schottelius M
EJNMMI research – 2024 Aug 28
TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer.
Kortleve D, Hammerl D, van Brakel M, (…), Martens JWM, Abbott RJM, Debets R
Cancer discovery – 2024 Aug 22
